Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Typical Use (research/clinical settings) Form : Injected subcutaneously near injury or intramuscular, sometimes taken orally in capsules (less studied)
Published clinical guidelines from organizations including the American Society of Metabolic and Bariatric Surgery and the Obesity Medicine Association have identified GLP-1 receptor agonists as appropriate pharmacological interventions in patients with a BMI of 30 or above (classified as obesity), or BMI of 27 or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea - the same criteria framework used by the FDA in evaluating GLP-1 medications for their obesity management indications
Investment Thesis GLP-1s, also known as glucagon-like peptide-1, is a medication used for weight loss and diabetes management
Reviews referencing personal health outcomes are summarized editorially
Current Regulatory Status of Retatrutide in the UK Retatrutide holds no MHRA or EMA marketing authorisation and is not legally available as a licensed medicine in the UK
US$ 22.89
US$ 29.31
US$ 20.06
